Business Context and Reporting Period
This Form 8-K is a current report filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on February 25, 2016. The filing serves to announce the company's financial results for the quarter and the full year ended December 31, 2015. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
No specific material changes versus the prior comparable period are quantified in the body of this Form 8-K. The document solely acts as a notification that the results for the period ended December 31, 2015, have been announced.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the information in the report and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation by reference.
Investor Verification Checklist
- Verify the correct registrant name is OvaScience, Inc., as the request metadata incorrectly listed Tempest Therapeutics, Inc.
- Locate and review Exhibit 99.1 (Press Release dated February 25, 2016) to obtain actual financial figures for the quarter and year ended December 31, 2015.
- Confirm the company's principal executive office address: 9 Fourth Avenue, Waltham, Massachusetts 02451.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.